Key result
Furoscix use at home was associated with a reduced mean 30-day heart failure-related healthcare cost of $16,995 per patient compared with matched hospitalized controls.
Why the study?
To compare heart failure costs of Furoscix use at home compared with inpatient intravenous diuresis.
Does subcutaneous furosemide (Furoscix) reduce 30-day heart failure-related healthcare costs in chronic heart failure patients presenting to the emergency department with worsening congestion compared to inpatient IV diuresis?
Case-Control (n=90)
Does subcutaneous furosemide (Furoscix) reduce 30-day heart failure-related healthcare costs in chronic heart failure patients presenting to the emergency department with worsening congestion compared to inpatient IV diuresis?
At-home subcutaneous furosemide infusion significantly reduces 30-day heart failure-related healthcare costs compared to short-stay inpatient intravenous diuresis.
Answers are grounded in this paper and cite their sources.
Home Furoscix may reduce 30-day HF costs versus brief hospitalization; leaves open need for RCTs to confirm safety and efficacy.
Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for ≤7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <72 h. Results: Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. Sixty-six control patients identified and were well-matched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p < 0.001). Conclusion: Furoscix use was associated with significant reductions in 30-day HF-related healthcare costs versus matched hospitalized controls.
No takes yet. Share an insight, caveat, or question.
Bensimhon et al. (2023) conducted a case-control in Heart failure (n=90). Furoscix vs. Matched historical patients hospitalized for <72 h receiving inpatient intravenous diuresis was evaluated on 30-day heart failure-related healthcare costs (reduced mean cost of $16,995, p=< 0.001). Furoscix use at home was associated with a reduced mean 30-day heart failure-related healthcare cost of $16,995 per patient compared with matched hospitalized controls.
Synapse has enriched 10 related papers. Consider them for comparative context: